Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 1/20 | 0.40 |
| ▸ | SELE | P16581 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859636 | 0.86 | ICAM1 (0.39) | ICAM1SELECREBBPEP300KMT2A | |
| SCHEMBL23178133 | 0.86 | CREBBP (0.40) | ICAM1SELECREBBPEP300KMT2A | |
| SCHEMBL14949940 | 0.85 | CREBBP (0.41) | ICAM1SELECREBBPEP300KMT2A | |
| SCHEMBL12141797 | 0.83 | ICAM1 (0.42) | ICAM1SELECREBBPEP300KMT2A | |
| SCHEMBL14065905 | 0.83 | ICAM1 (0.42) | ICAM1SELECREBBPEP300KMT2A | |
| SCHEMBL24858719 | 0.82 | ICAM1 (0.37) | ICAM1SELECREBBPEP300KMT2A | |
| SCHEMBL4317051 | 0.81 | ICAM1 (0.45) | ICAM1SELECREBBPEP300KMT2A | |
| SCHEMBL20857107 | 0.81 | KMT2A (0.45) | ICAM1SELECREBBPEP300KMT2A | |
| SCHEMBL8321396 | 0.81 | NPC1 (0.50) | ICAM1SELEKMT2AMEN1KDM4C | |
| SCHEMBL12139817 | 0.81 | ALDH1A1 (0.41) | ICAM1SELECREBBPEP300KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081310-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024081309-A1 | ENGINEERED CELLS AND IMPLANTABLE ELEMENTS FOR TREATMENT OF DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024006544-A2 | COVALENTLY CROSSLINKED POLYSACCHARIDES AND METHODS OF USE THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006551-A2 | COVALENTLY CROSSLINKED POLYSACCHARIDES AND METHODS OF USE THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| WO-2023147053-A2 | THERAPIES FOR MUCOPOLYSACCHARIDOSIS TYPE 6 | SIGILON THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147042-A2 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING CNS DISORDERS | SIGILON THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230233679-A1 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTS | SIGILON THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023129726-A2 | MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023076620-A1 | COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210002433-A1 | BIOCOMPATIBLE HYDROGEL CAPSULES AND PROCESS FOR PREPARING SAME | SIGILON THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020198685-A1 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING FABRY DISEASE | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198695-A1 | COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY | SIGILON THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| WO-2019195055-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195056-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019067766-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | SIGILON THERAPEUTICS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233679-A1 | COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTS | MYD88, CD4, CD74 | ICAM1 159/4885SELE 211/4885CREBBP 600/4885 |
| US-20210002433-A1 | BIOCOMPATIBLE HYDROGEL CAPSULES AND PROCESS FOR PREPARING SAME | ACMSD, ALG1, COL2A1 | ICAM1 2483/4885SELE 3377/4885CREBBP 1140/4885 |
| US-20210145759-A1 | IMPLANTABLE PARTICLES AND RELATED METHODS | TNNT2, TNNI3, TNNC1 | ICAM1 1367/4885SELE 2038/4885CREBBP 2695/4885 |
| US-20210060205-A1 | AFIBROTIC COMPOUNDS, DEVICES, AND USES THEREOF | TGFB2, TGFB1, COL2A1 | ICAM1 1167/4885SELE 1459/4885CREBBP 1354/4885 |
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | ICAM1 1528/4885SELE 1672/4885CREBBP 72/4885 |
| US-20210145889-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING STEM CELLS | MSI2, CXCL12, SOST | ICAM1 1253/4885SELE 574/4885CREBBP 576/4885 |
| US-20200263196-A1 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | ALDH1A2, MYOC, PDE6C | ICAM1 500/4885SELE 192/4885CREBBP 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.